金城医药上市14周年：归母净利润增长251%，市值较峰值蒸发67%

Core Insights - Jincheng Pharmaceutical has experienced significant growth since its listing in June 2011, with its market capitalization increasing from 2.465 billion yuan to 5.862 billion yuan, reflecting a deep focus on the pharmaceutical intermediate sector [1][6] - The company's main business includes the research, production, and sales of cephalosporin antibiotic intermediates, with the highest revenue contribution coming from formulation products at 35.30% [3] - Over the 14 years since its IPO, Jincheng Pharmaceutical has achieved a cumulative profit growth of 251.45%, with net profit reaching 197 million yuan in the latest fiscal year [3][4] Financial Performance - Revenue has shown stable growth, increasing from 2.962 billion yuan in 2020 to 3.373 billion yuan in 2024 [4] - The company has recovered from a loss of 489 million yuan in 2020 to a net profit of 197 million yuan in 2024, indicating a significant turnaround in profitability [4] - The company's net profit has fluctuated, with 7 out of 14 years showing profit growth, highlighting a volatile earnings trend [3] Market Capitalization - Since its IPO, Jincheng Pharmaceutical's market value has increased by 138%, peaking at 17.555 billion yuan in July 2021 [6] - As of June 20, the company's market capitalization was 5.862 billion yuan, down 11.693 billion yuan from its peak, representing a 66.61% decrease [6]